financetom
Business
financetom
/
Business
/
Shopify Making 'Meaningful' Share Gains in Enterprise Ecommerce, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Shopify Making 'Meaningful' Share Gains in Enterprise Ecommerce, UBS Says
Jul 28, 2025 10:03 AM

12:39 PM EDT, 07/28/2025 (MT Newswires) -- Shopify ( SHOP ) has made "meaningful" share gains in enterprise ecommerce since the launch of Commerce Components by Shopify ( SHOP ) in 2023, UBS Securities said in a note Monday.

The brokerage said enterprise customers could add about 4% to 5% to Shopify's ( SHOP ) annual gross merchandise volume growth above the broader retail ecommerce market over the next decade. It framed enterprise as one of three pillars, along with international and point-of-sale, driving the company's long-term expansion strategy.

The offering provides additional flexibility that allows the company to replace customized ecommerce platforms developed by large merchants in-house, the firm said.

Aside from the added flexibility, UBS said Shopify's ( SHOP ) success in enterprise has been due to the expansion of its partner network and on-ramps into Shopify ( SHOP ), investment behind its go-to-market approach and total cost of ownership considerations.

The firm also took note of the company's unified commerce offering that allows the integration of an enterprise's front and back-end systems into one platform, compared with more siloed alternatives.

UBS has a neutral rating on the company's stock with a $110 price target.

The company's shares were up over 2% in recent trading.

Price: 127.40, Change: +2.97, Percent Change: +2.39

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Interdigital Insider Sold Shares Worth $261,030, According to a Recent SEC Filing
Interdigital Insider Sold Shares Worth $261,030, According to a Recent SEC Filing
Aug 21, 2025
04:46 PM EDT, 08/21/2025 (MT Newswires) -- Rajesh Pankaj, Chief Technology Officer, on August 20, 2025, sold 1,000 shares in Interdigital (IDCC) for $261,030. Following the Form 4 filing with the SEC, Pankaj has control over a total of 67,122 common shares of the company, with 67,122 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1405495/000162828025040976/xslF345X05/wk-form4_1755808869.xml ...
--Parker-Hannifin Increases Stock Buyback Program to 20 Million Shares
--Parker-Hannifin Increases Stock Buyback Program to 20 Million Shares
Aug 21, 2025
05:23 PM EDT, 08/21/2025 (MT Newswires) -- Parker-Hannifin ( PH ) said Thursday the board has approved a revision to the motion and technology company's existing share repurchase program, allowing up to a total of 20 million shares to be repurchased. Shares were largely flat in the afterhours activity. ...
Ardent Health Partners Files for $500 Million Mixed Shelf Offering, Launches Secondary Offering
Ardent Health Partners Files for $500 Million Mixed Shelf Offering, Launches Secondary Offering
Aug 21, 2025
05:24 PM EDT, 08/21/2025 (MT Newswires) -- Ardent Health Partners (ARDT) filed Thursday a shelf registration statement to offer and sell up to $500 million in a combination of securities such as common stock, preferred stock, and debt securities. As part of the filing with the Securities and Exchange Commission, it also launched a secondary offering of up to 120.5...
Vanda Asks FDA Commissioner to Review Decision to Uphold Approval of Two Generic Versions of Hetlioz Drug
Vanda Asks FDA Commissioner to Review Decision to Uphold Approval of Two Generic Versions of Hetlioz Drug
Aug 21, 2025
05:24 PM EDT, 08/21/2025 (MT Newswires) -- Vanda Pharmaceuticals ( VNDA ) said late Thursday it has asked the US Food and Drug Administration commissioner Martin Makary to review the decision by the outgoing director of Center for Drug Evaluation and Research, Jacqueline Corrigan-Curay, that upholds approval of two generic versions of the Hetlioz drug. Hetlioz is used to treat...
Copyright 2023-2026 - www.financetom.com All Rights Reserved